Antifungal dynamics of LY 303366, an investigational Echinocandin B analog, against Candida ssp.

Diagnostic Microbiology and Infectious Disease

Volumn 26, Issue 3-4, 1996, Pages 125-131

  Ernst, Michael E ^a   Klepser, Michael E ^a   Wolfe, Erika J ^a   Pfaller, Michael A ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ECHINOCANDIN B;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDIASIS; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA; CANDIDA ALBICANS; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; TIME FACTORS;

EID: 0030295028     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(96)00202-7     Document Type: Article

References (17)

1. Current WL, Boylan CJ, Raab PP (1993) Anti-pneumocystis activity of LY303366 and other echinocandin β analogs. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington DC: American Society for Microbiology, (abst 368), p. 186.
2. Debono M, Gordee RS (1994) Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 48:471-497.
3. Debono M, Turner WW, LaGrandeur LM, Molloy RM, Burkhardt FJ, Rodriguez M, Zweifel MJ, Nissen JS, Clingerman K, Gordee RS, Zeckner DJ, Parr TR, Tang J (1993) LY303366 - A new semisynthetic lipopeptide antifungal agent related to echinocandin β. Synthetic and structure activity studies. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington DC: American Society for Microbiology, (abst 359), p. 185.
4. Hoban D, Kabani A, Karlowsky J, Friesen M, Harding G, Turik M, Zhanel G (1996) Evaluation of in vitro activity of a new echinocandin, LY303366 against systemic isolates of Candida ssp. and Cryptococcus neoformans. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst F47), p. 108.
5. Jarvis WR (1995) Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20:1526-1530.
6. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA (1996a) Characterization of the fungicidal dynamics of fluconazole (FLU) and amphotericin B (AB) against C. albicans via kill-curve methodologies. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst E51), p. 90.
7. Klepser ME, Wolfe EJ, Pfaller MA (1996b) Characterization of the fungicidal dynamics of fluconazole (FLU) and amphotericin B (AMB) against Cryptococcus neoformans via kill-curve methodologies. In Program and Abstracts of the Infectious Disease Society of America Annual Meeting (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst 77), p. 50.
8. Lucas R, Desante K, Hatcher B, Hemingway J, Lachno R, Brooks S, Turik M (1996) LY303366 single dose pharmacokinetics and safety in healthy male volunteers. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst F50), p. 108.
9. National Committee for Clinical Laboratory Standards (NCCLS) (1992) Reference method for broth dilution antifungal susceptibility testing of yeast: proposed standard M27-P. Villanova, PA: NCCLS.
10. Pfaller MA (1995) Epidemiology of candidiasis. J Hosp Infect 30(suppl):329-338.
11. Pfaller MA, Messer S, Coffman S (1996) In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366, and comparative antifungal agents. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst F48), p. 108.
12. Stevens DA, Martinez M, Devine MJ (1996) Antifungal activity of LY303366 (LY), an echinocandin beta glucan synthase inhibitor (GSI). In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst F46), p. 107.
13. Tang J, Parr TR, Turner W, Debono M, LaGrandeur L, Burkhardt F, Rodriguez M, Zweifel M, Nissen J, Clingerman K (1993) LY303366: A noncompetitive inhibitor of (1,3)-β-D-glucan synthases from Candida albicans and Aspergillus fumigatus. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst 367), p. 186.
14. Wolfe EJ, Klepser ME, Pfaller MA (1996) Antifungal dynamics of amphotericin B (AMB) and fluconazole (FLU) in combination against Candida albicans. In Program and Abstracts of the Infectious Disease Society of America 34th Annual Meeting (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst 76), p. 49.
15. Zeckner D, Butler T, Boylan C, Boyll, B, Lin Y, Raab P, Schmidtke J, Current W (1993a) LY303366, activity against systemic aspergillosis and histoplasmosis in murine models. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst 364), p. 186.
16. Zeckner D, Butler T, Boylan C, Boyll B, Lin Y, Raab P, Schmidtke J, Current W (1993b) LY303366, activity in a murine systemic candidiasis model. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). Washington, DC: American Society for Microbiology, (abst 365), p. 186.
17. Zeckner D, Butler T, Boylan C, Boyll B, Watson P, Current W (1995) In vitro evaluation of LY303366 against Candida ssp. clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, (abst F98), p. 130.